JCTT

Jiangsu Chia Tai Tianqing Pharmaceutical Group (CTTQ), often referred to as JCTT in clinical contexts, is a premier Chinese pharmaceutical enterprise and the principal subsidiary of Sino Biopharmaceutical. The company is a dominant force in the Chinese market, particularly within the oncology, hepatology, and respiratory therapeutic areas. CTTQ's portfolio is anchored by its flagship product, FocusV (anlotinib), a multi-target tyrosine kinase inhibitor that has achieved significant commercial success in treating various solid tumors. Beyond small molecules, the company has aggressively expanded into biologics, developing a robust pipeline of monoclonal antibodies, bispecifics, and cell therapies. With extensive manufacturing capabilities and a large-scale commercial infrastructure, CTTQ serves as a key partner for international biotech firms seeking to navigate the Chinese healthcare landscape. The company is consistently ranked among the top innovative pharmaceutical firms in China, driven by its significant investment in R&D centers across Lianyungang, Nanjing, and Shanghai.